NY-AQARA
9.7.2024 09:01:31 CEST | Business Wire | Press release
Aqara, a global leader and pioneer in IoT, today announced the official launch of the highly anticipated Smart Lock U200. Designed as a retrofit, keyless solution for home access management, the U200 lock offers unparalleled convenience, advanced security features, and seamless interoperability across smart home ecosystems and devices thanks to its native Matter compatibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709404547/en/
Aqara Smart Lock U200 (Photo: Business Wire)
The Aqara Smart Lock U200 brings a modern keyless lifestyle to a broad array of homeowners and renters, and provides multiple secure door entry options, including Apple home keys, which allow iOS users to unlock effortlessly by tapping a compatible iPhone or Apple Watch. The U200 distinguishes itself as one of the first Matter-over-Thread locks to support home key unlocking and is also one of the first retrofit smart locks to feature Apple home key.
Other unlocking methods of the Smart Lock U200 include:
- Fingerprint recognition: Fast and secure access with the high-precision fingerprint reader.
- PIN codes: Personalized codes can be entered on the included, pre-paired wireless keypad. Moreover, Aqara Home users can manage guess access easily with not only periodic passwords but also one-time passwords that can be remotely created, shared, and used even when the lock is disconnected from any platforms.
- Mobile apps and voice assistants: Remote control via Aqara Home, Alexa, Apple Home/Siri, Google Home/Google Assistant, SmartThings, Home Assistant, and more1.
- Aqara NFC cards: Quick and easy unlocking using Aqara’s NFC key fobs2.
- Traditional keys: emergency access with the original keys.
The U200 lock stands out with its hassle-free retrofit design, allowing homeowners and renters to upgrade their existing locks - such as Euro mortise locks and US deadbolt locks - without the need to change keys or modify the door structure. This lock provides an instant smart update to most homes and is suitable for DIY installation, as attaching the U200 over the existing lock is simple and requires no tool apart from a screwdriver.
Security is a top priority with the Smart Lock U200. It features advanced encryption to protect against hacking, a tamper alarm on the wireless keypad, and an auto-lock function that secures the door automatically after a set period. Additionally, the U200 provides real-time notifications to keep users informed about their home’s security status.
The U200 retains many popular features of the previous Aqara locks, such as local and encrypted storage of sensitive data like fingerprints and passwords, anti-peep PIN code protection, Do-Not-Disturb mode, Passage mode, and Night Latch mode3. Furthermore, it adds thoughtful features like quiet unlock mode to minimize the noise level, pull spring feature for handle-less or inward-opening doors, as well as turn-to-lock and turn-to-unlock functions.
Built upon the energy-efficient Thread protocol, the U200 lock is designed for extended use. The lock runs on rechargeable Li-Ion batteries and boasts a battery life of up to 6 months between each charge. Additionally, the IPX5-rated wireless keypad is operable with AAA batteries or existing doorbell wiring, which allows for uninterrupted usage4.
The Smart Lock U200 is now available at Aqara’s Amazon brand stores throughout North America (US, Canada) and Europe (France, Germany, Italy, Netherlands, Poland, Spain, UK), as well as through select Aqara retailers worldwide.
The U200 lock is compatible with Euro mortise locks with Emergency Function, and supports various cylinders including EU profile cylinders, select Scandi profile cylinders and UK oval cylinders. An Emergency Function enables the cylinder to be unlocked from the outside using a key, even if another key is already inserted on the inside. Adjustable cylinders are sold separately by Aqara. The U200 is also compatible with single-cylinder deadbolt locks.
For more information on the U200 lock and its compatibility, please visit our website.
- A Matter controller with Thread Border Router functionality is required to connect the Smart Lock U200 to any third-party Matter-enabled system.
- Aqara NFC card is available in-box with the Smart Lock U200 Kit or sold separately.
- Some of these features may not be available at the time of launch, and will be added via subsequent OTA updates.
- The 6-month battery life is based on the assumption of 8 cycles of unlocking and locking per day. To operate the wireless keypad with the existing doorbell wiring, a 12V-24V AC/DC power supply is required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709404547/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom